by rss feed | Sep 14, 2026 | News Feeds
A US cohort study of 5,520 children found no overall association between prenatal exposure to fluoride in public drinking water and internalizing or externalizing behavioral problems across the primary analyses. Exploratory analyses identified some associations with...
by rss feed | Sep 13, 2026 | IPS cells, News Feeds, Reprogramming, weekly reads
Do you buy the idea of using in vivo reprogramming to fight aging? How about to treat certain diseases? The stream of research pubs and news articles continues to grow. Before we jump into weekly reads including on reprogramming applications, on the 20th anniversary...
by rss feed | Sep 12, 2026 | News Feeds
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at...
by rss feed | Sep 12, 2026 | News Feeds
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from...
by rss feed | Sep 12, 2026 | News Feeds
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic...
by rss feed | Sep 12, 2026 | News Feeds
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy...
